1. Home
  2. IHG vs BIIB Comparison

IHG vs BIIB Comparison

Compare IHG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercontinental Hotels Group

IHG

Intercontinental Hotels Group

HOLD

Current Price

$133.37

Market Cap

17.0B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.52

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHG
BIIB
Founded
1777
1978
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
IHG
BIIB
Price
$133.37
$181.52
Analyst Decision
Sell
Buy
Analyst Count
2
23
Target Price
N/A
$176.48
AVG Volume (30 Days)
150.6K
1.9M
Earning Date
01-01-0001
10-30-2025
Dividend Yield
1.26%
N/A
EPS Growth
21.99
N/A
EPS
4.70
10.97
Revenue
$5,120,000,000.00
$10,065,900,000.00
Revenue This Year
N/A
$3.61
Revenue Next Year
$6.33
N/A
P/E Ratio
$26.61
$16.52
Revenue Growth
33.89
4.77
52 Week Low
$94.78
$110.04
52 Week High
$137.73
$185.17

Technical Indicators

Market Signals
Indicator
IHG
BIIB
Relative Strength Index (RSI) 56.93 72.92
Support Level $132.36 $174.53
Resistance Level $137.73 $182.94
Average True Range (ATR) 2.06 5.22
MACD 0.23 0.25
Stochastic Oscillator 67.02 83.54

Price Performance

Historical Comparison
IHG
BIIB

About IHG Intercontinental Hotels Group

InterContinental Hotels Group operates 987,000 rooms across 19 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: